April 2010
Volume 51, Issue 13
ARVO Annual Meeting Abstract  |   April 2010
Topical EGCG for Treatment of Dry Eye Disease
Author Affiliations & Notes
  • H. Lee
    Ophthalmology, Schepens Eye Research Institute, Boston, Massachusetts
  • R. Dana
    MEEI/SERI Harvard Ophthalmology, Boston, Massachusetts
  • Footnotes
    Commercial Relationships  H. Lee, None; R. Dana, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science April 2010, Vol.51, 6272. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      H. Lee, R. Dana; Topical EGCG for Treatment of Dry Eye Disease. Invest. Ophthalmol. Vis. Sci. 2010;51(13):6272.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : Epigallocatechin gallate (EGCG), a component of green tea catechin with the strong biological activity, has been reported to have anti-inflammatory and immunomodulatory activities. The aim of this study is to evaluate the efficacy of topical EGCG for treatment of dry eye disease (DED).

Methods: : Fifty C57BL/6 mice were housed in the controlled environment chamber to induce the murine DED model. Topical 0.1% EGCG or vehicle as control was applied to the eyes. Corneal fluorescein staining and the number of corneal CD11b+ cells were assessed in the different groups. Expression of cytokines IL-1β, tumor necrosis factor (TNF)-α, and monocyte chemotactic protein (MCP)-1 were evaluated by real-time PCR in the corneas and conjunctivae at day 9.

Results: : Treatment with topical EGCG showed a significant decrease in corneal fluorescein staining compared with the vehicle (33%, P<.001) and untreated controls (48%, P<.001) as well as a significant decrease in infiltration of CD11b+ cells compared with the vehicle at periphery and center (23.3% [P=.002], 39.9% [P=.030]). EGCG treatment was also associated with a significant decrease in the corneal expression of IL-1β and MCP-1 compared with the vehicle (40.5%[P=.002], 52.8% [P=.005]).

Conclusions: : Topical EGCG treatment is able to reduce the clinical signs and inflammatory changes in the cornea in DED as evidenced by decreased inflammatory cytokine expression and the infiltration of CD11b+ cells.

Keywords: cornea: tears/tear film/dry eye 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.